Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

478
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

539
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
539
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

511
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

591
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction.

European journal of heart failure·2024
Same author

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

Journal of the American College of Cardiology·2024
Same author

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

The New England journal of medicine·2024
Same author

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.

Circulation·2024
Same author

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.

Nature medicine·2024
Same author

Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation.

JAMA cardiology·2024

相关实验视频

Updated: Mar 18, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

用保存的喷射部分对心力衰竭的表型特异性治疗:多器官路线图

Sanjiv J Shah1, Dalane W Kitzman1, Barry A Borlaug1

  • 1From Division of Cardiology, Department of Medicine, and the Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Sections on Cardiovascular Medicine and Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, (B.A.B.); Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (L.v.H., W.J.P.); Department of Cardiology, Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands (L.v.H.); Department of Medicine, Medical University of South Carolina (MUSC) and the RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z.); and Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD (D.A.K.).

Circulation
|July 1, 2016
PubMed
概括
此摘要是机器生成的。

用保存喷射分数 (HFpEF) 治疗心力衰竭需要解决并发症和多种表型. 个性化策略针对HFpEF特定的信号通路,以改善结果.

关键词:
这种疾病心脏衰竭心脏衰竭,腹筋衰竭现象型治疗药物左心室功能

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

相关实验视频

Last Updated: Mar 18, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

科学领域:

  • 心脏病学
  • 内部医学
  • 翻译研究

背景情况:

  • 心脏衰竭与保存的喷射分数 (HFpEF) 是一个日益严重的临床挑战,占心脏衰竭病例的50%.
  • 与减少喷射分数的HF不同,HFpEF对传统的神经幽默抑制疗法表现出耐药性.
  • 独特的系统和心肌信号通路,以及表型多样性,有助于HFpEF的复杂性.

研究的目的:

  • 提出一种新的HFpEF处理策略,考虑到其特定的信号机制和表型变异.
  • 阐明心脏外伴随性疾病在HFpEF中推动心脏重塑和功能障碍的作用.
  • 在已识别的信号级联中确定潜在的治疗目标.

主要方法:

  • 对HFpEF病理生理学的当前文献的综述,重点是系统性炎症和内皮功能障碍.
  • 分析将共患病 (代谢风险,高血压,功能衰竭) 与心脏重塑联系起来的信号通路.
  • 在HFpEF中探索针对特定分子和细胞过程的针对性干预措施.

主要成果:

  • 外心并发症通过全身炎症和冠状动脉微血管内皮功能障碍驱动HFpEF.
  • 这些机制导致左心室扩张功能障碍,间歇性纤维化和心肌细胞硬化.
  • 确定了多种治疗点,包括卡路里限制,他类药物,PDE5抑制剂,运动,利尿剂,酸盐-酸盐, neprilysin/ PDE9抑制剂和螺旋.

结论:

  • 由于其表型多样性,个性化治疗方法对于管理HFpEF至关重要.
  • 针对HFpEF特定的信号级联为治疗开发提供了一个有前途的途径.
  • 考虑HFpEF表现和倾向的矩阵方法可以指导个性化治疗选择.